Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Length of Symptoms Before Referral: Prognostic Variable for High-grade Soft Tissue Sarcoma?</title><author><name sortKey="Rougraff, Bruce T" sort="Rougraff, Bruce T" uniqKey="Rougraff B" first="Bruce T." last="Rougraff">Bruce T. Rougraff</name><affiliation><nlm:aff id="Aff1"> OrthoIndy, 8450 Northwest Blvd, Indianapolis, IN 46278 USA</nlm:aff></affiliation></author><author><name sortKey="Lawrence, Jackie" sort="Lawrence, Jackie" uniqKey="Lawrence J" first="Jackie" last="Lawrence">Jackie Lawrence</name><affiliation><nlm:aff id="Aff1"> OrthoIndy, 8450 Northwest Blvd, Indianapolis, IN 46278 USA</nlm:aff></affiliation></author><author><name sortKey="Davis, Kenneth" sort="Davis, Kenneth" uniqKey="Davis K" first="Kenneth" last="Davis">Kenneth Davis</name><affiliation><nlm:aff id="Aff1"> OrthoIndy, 8450 Northwest Blvd, Indianapolis, IN 46278 USA</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">22183474</idno><idno type="pmc">3270193</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3270193</idno><idno type="RBID">PMC:3270193</idno><idno type="doi">10.1007/s11999-011-2192-4</idno><date when="2011">2011</date><idno type="wicri:Area/Pmc/Corpus">000B16</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000B16</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Length of Symptoms Before Referral: Prognostic Variable for High-grade Soft Tissue Sarcoma?</title><author><name sortKey="Rougraff, Bruce T" sort="Rougraff, Bruce T" uniqKey="Rougraff B" first="Bruce T." last="Rougraff">Bruce T. Rougraff</name><affiliation><nlm:aff id="Aff1"> OrthoIndy, 8450 Northwest Blvd, Indianapolis, IN 46278 USA</nlm:aff></affiliation></author><author><name sortKey="Lawrence, Jackie" sort="Lawrence, Jackie" uniqKey="Lawrence J" first="Jackie" last="Lawrence">Jackie Lawrence</name><affiliation><nlm:aff id="Aff1"> OrthoIndy, 8450 Northwest Blvd, Indianapolis, IN 46278 USA</nlm:aff></affiliation></author><author><name sortKey="Davis, Kenneth" sort="Davis, Kenneth" uniqKey="Davis K" first="Kenneth" last="Davis">Kenneth Davis</name><affiliation><nlm:aff id="Aff1"> OrthoIndy, 8450 Northwest Blvd, Indianapolis, IN 46278 USA</nlm:aff></affiliation></author></analytic><series><title level="j">Clinical Orthopaedics and Related Research</title><idno type="ISSN">0009-921X</idno><idno type="eISSN">1528-1132</idno><imprint><date when="2011">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Background</title><p>It is commonly assumed patients with high-grade soft tissue sarcomas who are diagnosed and treated quickly after the first onset of symptoms fare better than those with longer symptoms before treatment. The literature contains no substantive data to support this assumption for soft tissue sarcomas, particularly for high-grade lesions.</p></sec><sec><title>Questions/purposes</title><p>We examined selected potential prognostic factors for high-grade soft tissue sarcoma and determined whether the time from first symptom to diagnosis has an impact on survival or disease-free survival and whether subcutaneous sarcomas are diagnosed more quickly than deep sarcomas.</p></sec><sec><title>Methods</title><p>We retrospectively reviewed 381 consecutive patients treated for high-grade soft tissue sarcoma between 1992 and 2007. Each patient’s time from first symptom (pain and/or palpable mass) was prospectively entered into a surgical oncology database. The patients were followed for disease recurrence and survival. We compared length of symptoms with disease-free survival, overall survival, metastases at diagnosis, tumor size, and patient age. Minimum followup was 1 month (mean, 57 months; range, 1–201 months).</p></sec><sec><title>Results</title><p>The overall 5-year survival was 64.7% and disease-free survival was 54.5%. Tumor size and metastatic disease correlated with overall survival and disease-free survival but not length of symptoms. Length of symptoms did not correlate with overall survival or disease-free survival.</p></sec><sec><title>Conclusions</title><p>Our data do not support the assumption that longer length of symptoms before diagnosis predicts worse overall survival, disease-free survival, or metastatic disease at diagnosis.</p></sec><sec><title>Level of Evidence</title><p>Level II, prognostic study. See Guidelines for Authors for a complete description of levels of evidence.</p></sec></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Orthop Relat Res</journal-id><journal-title-group><journal-title>Clinical Orthopaedics and Related Research</journal-title></journal-title-group><issn pub-type="ppub">0009-921X</issn><issn pub-type="epub">1528-1132</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22183474</article-id><article-id pub-id-type="pmc">3270193</article-id><article-id pub-id-type="publisher-id">2192</article-id><article-id pub-id-type="doi">10.1007/s11999-011-2192-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Symposium: 2010 Musculoskeletal Tumor Society</subject></subj-group></article-categories><title-group><article-title>Length of Symptoms Before Referral: Prognostic Variable for High-grade Soft Tissue Sarcoma?</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Rougraff</surname><given-names>Bruce T.</given-names></name><degrees>MD</degrees><address><email>brougraff@aol.com</email></address><xref ref-type="aff" rid="Aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Lawrence</surname><given-names>Jackie</given-names></name><degrees>MA</degrees><xref ref-type="aff" rid="Aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Davis</surname><given-names>Kenneth</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="Aff1"></xref></contrib><aff id="Aff1"> OrthoIndy, 8450 Northwest Blvd, Indianapolis, IN 46278 USA</aff></contrib-group><pub-date pub-type="epub"><day>20</day><month>12</month><year>2011</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2012</year></pub-date><volume>470</volume><issue>3</issue><fpage>706</fpage><lpage>711</lpage><permissions><copyright-statement>© The Association of Bone and Joint Surgeons® 2011</copyright-statement></permissions><abstract id="Abs1"><sec><title>Background</title><p>It is commonly assumed patients with high-grade soft tissue sarcomas who are diagnosed and treated quickly after the first onset of symptoms fare better than those with longer symptoms before treatment. The literature contains no substantive data to support this assumption for soft tissue sarcomas, particularly for high-grade lesions.</p></sec><sec><title>Questions/purposes</title><p>We examined selected potential prognostic factors for high-grade soft tissue sarcoma and determined whether the time from first symptom to diagnosis has an impact on survival or disease-free survival and whether subcutaneous sarcomas are diagnosed more quickly than deep sarcomas.</p></sec><sec><title>Methods</title><p>We retrospectively reviewed 381 consecutive patients treated for high-grade soft tissue sarcoma between 1992 and 2007. Each patient’s time from first symptom (pain and/or palpable mass) was prospectively entered into a surgical oncology database. The patients were followed for disease recurrence and survival. We compared length of symptoms with disease-free survival, overall survival, metastases at diagnosis, tumor size, and patient age. Minimum followup was 1 month (mean, 57 months; range, 1–201 months).</p></sec><sec><title>Results</title><p>The overall 5-year survival was 64.7% and disease-free survival was 54.5%. Tumor size and metastatic disease correlated with overall survival and disease-free survival but not length of symptoms. Length of symptoms did not correlate with overall survival or disease-free survival.</p></sec><sec><title>Conclusions</title><p>Our data do not support the assumption that longer length of symptoms before diagnosis predicts worse overall survival, disease-free survival, or metastatic disease at diagnosis.</p></sec><sec><title>Level of Evidence</title><p>Level II, prognostic study. See Guidelines for Authors for a complete description of levels of evidence.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Association of Bone and Joint Surgeons® 2012</meta-value></custom-meta></custom-meta-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B16 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000B16 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.31. |  |